Turn Therapeutics Inc. Operating Income
Turn Therapeutics Inc. (TTRX) reported Operating Income of -$1.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-12
- Turn Therapeutics Inc. operating income (loss) for the quarter ending 2026-06-30 was -$1.63M.
- Turn Therapeutics Inc. operating income (loss) for the quarter ending 2026-03-31 was -$1.25M.
- Turn Therapeutics Inc. operating income (loss) for the quarter ending 2025-12-31 was -$2.19M.
- Turn Therapeutics Inc. operating income (loss) for the quarter ending 2025-09-30 was -$1.91M.
- Turn Therapeutics Inc. operating income (loss) for fiscal 2025 was -$5.86M.
- Turn Therapeutics Inc. operating income (loss) for fiscal 2024 was -$1.80M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.63M 10-Q · filed 2026-08-12 | -$2.84M 10-Q · filed 2026-08-12 | -$5.07M derived: sum of 3 quarters · filed 2026-08-12 | -$6.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$1.25M 10-Q · filed 2026-05-11 | -$3.44M derived: sum of 2 quarters · filed 2026-05-11 | -$5.35M derived: sum of 3 quarters · filed 2026-05-11 | -$6.72M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.11M derived: sum of 2 quarters · filed 2026-03-31 | -$5.47M derived: sum of 3 quarters · filed 2026-08-12 | -$5.86M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$1.91M 10-Q · filed 2025-11-13 | -$3.28M derived: sum of 2 quarters · filed 2026-08-12 | -$3.67M 10-Q · filed 2025-11-13 | -$3.99M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$1.37M 10-Q · filed 2026-08-12 | -$1.75M 10-Q · filed 2026-08-12 | -$2.08M derived: sum of 3 quarters · filed 2026-08-12 | -$2.75M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$385.00K 10-Q · filed 2026-05-11 | -$713.95K derived: sum of 2 quarters · filed 2026-05-11 | -$1.39M derived: sum of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$328.96K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.00M derived: sum of 2 quarters · filed 2026-03-31 | -$1.80M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$672.99K 10-Q · filed 2025-11-13 | -$1.47M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |